Join Growin Stock Community!

永立榮6973.TW Overview

TW StockBiotech. & Medical
(No presentation for 6973)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

永立榮（6973）Overall Performance

永立榮（6973）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

永立榮（6973） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

永立榮（6973）Key Information

永立榮（6973）Profile

U-Neuron Biomedical, Inc. engages in the research and development of stem cell storage and separation technology, and treatment application technology. It focuses in the study of Amniotic Fluid Stem Cells, Olfactory Stem Cells, and Adipose-derived Stem Cells. The company was founded on September 4, 2015 and is headquartered in New Taipei, Taiwan.

永立榮（6973）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14.06
PB Ratio
1.75
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
75.89%
Net Margin
-146.99%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14.06
PB Ratio
1.75
Price-to-FCF
-
Gross Margin
75.89%
Net Margin
-146.99%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is 6973's latest earnings report released?

    The most recent financial report for 永立榮 (6973) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6973's short-term business performance and financial health. For the latest updates on 6973's earnings releases, visit this page regularly.

  • How much cash does 6973 have?

    At the end of the period, 永立榮 (6973) held Total Cash and Cash Equivalents of 179.96M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6973 go with three margins increasing?

    In the latest report, 永立榮 (6973) did not achieve the “three margins increasing” benchmark, with a gross margin of 65.91%%, operating margin of -70.69%%, and net margin of -58.56%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6973's profit trajectory and future growth potential.

default symbol

6973

永立榮

32.90D

-1.67%

(-0.02)